EANS-Adhoc: Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products

11.12.2009

Vienna (Austria) / London (UK), December 11, 2009 - Intercell and
GlaxoSmithKline Biologicals SA (GSK) today announced an agreement to
form a strategic alliance to accelerate the development and
commercialization of needle-free, patch-based vaccines. The agreement
will include Intercell's candidate vaccine for travelers' diarrhea
(TD) and an investigational single application pandemic influenza
vaccine, as well as the use of the patch technology for other
vaccines in GSK's portfolio.

Under the terms of the agreement, GSK will make an up-front cash
contribution of EUR 33.6 (USD 49.4) million, in addition to an equity
investment of up to EUR 84 (USD 123.5) million through a staggered
shareholding purchase option of up to 5 % in Intercell. Included in
the agreement are Intercell's investigational TD vaccine, currently
in Phase III, and an investigational single application pandemic
influenza vaccine in Phase II, as well as other potential future
patch vaccines.

"This new partnership is combining the forces of Intercell's
innovative needle-free vaccination program and technologies with a
vaccine leader's strength in development and commercialization. In
addition, we can pursue our business strategy of creating significant
shareholder value as an independent company whilst continuing to
develop one of the most innovative product pipelines in the
industry," says Gerd Zettlmeissl, Chief Executive Officer of
Intercell.

"This novel technology has real potential to change the way vaccines
are delivered in the future. GSK has an extensive portfolio of
vaccines and we believe needle-free vaccination could offer benefits
such as simplified administration and increased compliance." said
Jean Stephenne, President of GSK Biologicals. "This agreement
demonstrates how, as an integral part of our R&D program, we not only
look at new vaccines but also at alternative approaches to oral and
intramuscular administration."

Each year, approximately 20 million international travelers develop
TD while visiting endemic areas in Asia, Africa, and South America.
Currently, there is no vaccine available to address this medical
need. GSK and Intercell will collaborate on the TD Vaccine Patch,
currently in phase III, to commercialize this vaccine once it has
gained regulatory approval. The agreement will also include a
collaboration between the two companies to further develop and
co-market an innovative pandemic influenza vaccination approach.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market